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Background. A trial of empirical acid-suppressive therapy is the usual practice for most patients with symptoms of gastritis in
primary care. Aim. To assess the relative eﬃcacy of Troxipide and Ranitidine in patients with endoscopic gastritis over a four-week
period. Methods. In all, 142 patients were randomized to Troxipide (100mg tid) or Ranitidine (150mg bid) for a period of four
weeks. The severity of the signs of endoscopic gastritis at baseline and week 4 using a four-point scale and the subjective symptom
severity at baseline and week 2 & week 4 using a Visual analog scale (VAS) were documented. Results. Troxipide was found to be
superior to Ranitidine for both, the complete resolution and improvement of endoscopic gastritis. Higher proportion of patients
showed complete healing of erosions (88.14%), oozing (96.77%), and edema (93.88%) with Troxipide as compared to Ranitidine
(P<. 01). Patients receiving Troxipide also showed a greater improvement in the VAS scores for abdominal pain, bloating, and
heartburn (P<. 01). Both the drugs were found to be well tolerated. Conclusion. In patients with endoscopic gastritis, Troxipide,
with its superior rate of improvement, resolution of signs, and subjective clinical symptoms, can be considered as an alternative to
the commonly used antisecretory agents.
1.Introduction
Gastrointestinal disorders like gastritis are highly prevalent
diseases among the Asian population [1], with majority of
the patients approaching their general practitioners only
after the disease-related symptoms become more frequent
or more severe. These symptoms have been known to
cause marked disruption of physical, social, and emotional
well-being of the patients [2], and, hence, therapy is
generally directed at controlling these symptoms quickly and
eﬃciently.
Gastricantisecretoryagentslikethehistamine-2-receptor
antagonists (H2RAs), proton-pump inhibitors (PPIs), and
the Cytoprotective agents (antacids, sucralfate) have been
successfullyusedforyearsinthetreatmentofgastrointestinal
disorders like gastritis [3]. Despite many eﬀorts, the phar-
macological treatment of patients with gastritis using acid
suppressants usually achieves only partial symptomatic relief
in the majority of the cases [4].
Of late, however, the role of the cytoprotective agents
in strengthening the mucosal defensive factors is gaining
importance. It is now assumed that these drugs ultimately
balance the aggressive factors (acid, pepsin, H. pylori, and
bile salts) and defensive factors (mucin secretion, cellular
mucus, bicarbonate secretion, mucosal blood ﬂow, and cell
turnover) [5–7]. Although these drugs have brought about
remarkable changes in ulcer therapy, the eﬃcacy of these
drugs is still debatable.
Troxipide is a new gastric cytoprotective agent, which
neitherinhibitsacidsecretionnorhasacidneutralizingactiv-
ity, but has been clinically proven to heal gastritis and gastric
ulcers [8–10]. Troxipide has shown to inhibit neutrophil
mediated inﬂammation [11] and oxidative stress [11–15]
in addition to improving the gastric mucus composition
and output [9, 16]. Furthermore, it has been found to
increase the secretion of cytoprotective prostaglandins [10].
The gastric mucosal metabolism [17] and blood ﬂow [18]
are also enhanced by Troxipide. Nearly 60% of gastric ulcers2 Gastroenterology Research and Practice
were reported to be completely healed within 8 weeks of the
administration of 300mg/day of Troxipide [11].
Although preclinical data have found Troxipide to be a
more eﬃcacious agent than the prototype cytoprotectants
[13, 17, 19] and acid suppressants (famotidine and raniti-
dine) [20], there is limited clinical data on the comparative
eﬃcacy of Troxipide with other therapeutic agents used in
thetreatmentofgastrointestinaldisorders.Thisclinicalstudy
has been conducted to compare the relative eﬃcacy of a
cytoprotective agent, Troxipide, with an acid suppressive
agent, Ranitidine, in alleviating, over a four-week period, the
symptoms of gastritis.
2. Methods
This multicentric, randomized therapeutic trial was planned
to compare the eﬀects of Troxipide and Ranitidine on the
resolution of endoscopically proven gastritis for a period of
four weeks. The study was conducted in accordance with the
Declaration of Helsinki and its subsequent revisions and as
per the ICH Good Clinical Practice (GCP) guidelines. The
Central Independent Ethics Committee-Clinical Research,
New Delhi, India approved the protocol of the study.
2.1. Patients. Patients (between 18–65yrs), referred for
upper gastrointestinal endoscopy, were recruited from the
outpatient clinics of ﬁve hospitals across India. The primary
requirement for inclusion was the presence of endoscopic
gastritis, as diagnosed by the Sydney classiﬁcation. The main
exclusion criteria included presence of perforation or pyloric
stenosis,esophagealstrictureorintestinalobstruction,previ-
ous history of gastrointestinal disease (inﬂammatory bowel
disease, malabsorption syndromes, gastrointestinal malig-
nancy), recent gastrointestinal surgery, that is, within 30
days (vagotomy, Barrett’s esophagus and scleroderma), prior
administration of PPIs, H2RAs, prokinetic agents or any
other gastroprotective agent within 7 days of screening, and
a known history of hypersensitivity to study medications.
2.2. Study Design. After obtaining the informed consent, all
thepatientsunderwentacompletephysicalexamination,and
relevant demographic details were noted. Laboratory investi-
gations, which included complete blood count, hemoglobin,
occult blood and serology (ELISA) for Helicobacter pylori,
and upper gastrointestinal endoscopy, were carried out.
The patients were then randomized, based on a computer-
generated randomization sequence, to either the Troxipide
treatment arm or the Ranitidine treatment arm. They
received either Troxipide 100mg orally thrice daily or
Ranitidine 150mg orally twice daily for a period of 28 days.
General systemic and laboratory investigations were per-
formed before the administration of the study medication.
Followup visits were scheduled after week 2 and week 4 of
therapy.
The patient’s medication supply was divided into two
parts, administered at the time of enrollment and on day
14 (after week 2). Thus each investigator was provided
with medication supply for 50 patients: plastic containers
containing either 45 tablets of Troxipide or 30 tablets of
Ranitidine for each patient.
2.3. Assessments. The topography and severity of endoscopic
gastritis was classiﬁed according to the Sydney System of
Endoscopic Classiﬁcation [21, 22]. Based on the endoscopy,
the topography was noted as antrum, corpus, or both
(pangastritis). The severity of the ﬁndings from the upper
gastrointestinal endoscopy (carried out at baseline and week
4) were rated on a four-point scale: 1 (no erosion/absent), 2
(1–3erosions/mild),3(4–6erosions/moderate),and4(more
than 6 erosions/severe) [4].
The visual analog scale (VAS), a scoring system from 0
(lack of symptom) to 100 (high severity) [23], was used to
score the severity of the seven subjective clinical symptoms
of gastritis (abdominal pain, bloating, belching, nausea,
vomiting, loss of appetite, and heartburn) at baseline and
each follow up visit. These severity score were further graded
as: none (VAS score 0), mild (VAS score 1–30), moderate
(VAS score 31–60), and severe (VAS score 61–100) [24].
The patients and investigators were asked to rate the
tolerability of the study medications on a four-point scale:
0 (very good), 1 (good), 2 (fair), and 3 (poor).
Adverse events, if any, were reported during the followup
visits.
2.4. Outcome Measures. There were two primary outcome
measures considered, namely, the proportion of patients
achieving complete resolution of the endoscopic gastritis
(reduction of four-point scale score for individual endo-
scopic signs to 0 at end of therapy), and symptom relief
(proportion of patients achieving a reduction in VAS score
of at least 50 for the various clinical symptoms of gastritis
studied from baseline to week 2 and week 4). The other
secondary outcome measures were proportion of patients
showingimprovementinendoscopicgastritis(areductionof
severity of the baseline four-point scale score for individual
endoscopic ﬁndings at the end of week 4), the proportion
of patients showing VAS score of 0 at end of week 2 and
week 4 (Complete Symptomatic Resolution), the proportion
of patients showing a reduction of greater than 20 points in
V A Ss c o r e sf r o mb a s e l i n et ow e e k2a n dw e e k4( S y m p t o m
Improvement), and Treatment Tolerability.
2.5. Statistical Analysis. The sample size was calculated based
on the assumption that a diﬀerence of 20% in the control
group would be detected with a responder rate of 80% in the
test group and a dropout rate of 25%. Thus, a sample of 100
completed patients in each group was found to be suﬃcient
at 5% level of signiﬁcance and 80% power.
The paired Students t-test or Wilcoxon ranks test was
used to analyze the intraindividual diﬀerences between
baseline and posttreatment values while the intertreatment
diﬀerences were analyzed with the unpaired Student’s t-test
(when means were considered) or Fisher’s exact test (when
proportionswereconsidered).Alldataarepresentedasmean
± standard deviation (SD) unless stated otherwise. P value
less than.05 was considered signiﬁcant.Gastroenterology Research and Practice 3
Table 1: Baseline demographic and clinical characteristics of study
population.
Troxipide
(n = 71)
Ranitidine
(n = 71)
Sex (n,% )
Male 46 (64.78) 35 (49.30)
Female 25 (35.21) 36 (50.70)
Age (yrs), mean (±SD) 36.82 ±12.42 33.19 ±10.79
Body mass index (kg/m2),
mean (±SD) 24.12 ±4.49 23.95 ±4.33
Positive H. pylori urea breath
test 5 (7.04) 0 (0.0)
Endoscopic site of Gastritis (n,
%)
Antrum 19 (26.76) 30 (42.25)
Corpus 7 (9.86) 6 (8.45)
Antrum and Corpus
(Pangastritis) 45 (63.38) 33 (46.47)
Endoscopic Evidences (n,% )
Erosion 59 (83.1) 55 (77.46)
Oozing 31 (43.66) 19 (26.76)
Redness 67 (94.36) 63 (88.73)
Edema 49 (69.01) 43 (60.56)
Gastritis clinical symptoms (n,
%)
Abdominal Pain 71 (100.0) 71 (100.0)
Bloating 67 (94.36) 65 (91.55)
Belching 44 (61.97) 39 (54.93)
Nausea 51 (71.83) 50 (70.42)
Vomiting 14 (19.72) 13 (18.31)
Loss of appetite 29 (40.85) 22 (30.99)
Heartburn 58 (81.69) 49 (69.01)
3. Results
One hundred and forty-four patients with symptomatic
gastritis or dyspepsia were randomized into two groups;
72 patients received Troxipide while 72 patients received
Ranitidine. In two patients, one from each group, no
followup data were available; they withdrew from the trial
after baseline evaluations.
3.1. Patient’s Proﬁle. The demographic and baseline clinical
characteristics of the 142 patients (71 in the Troxipide group
and 71 in the Ranitidine group) included in the study are
giveninTable 1.Baselinesystemicexaminationswerenormal
in all patients; however, gastrointestinal system examination
was found to be abnormal in 8.45% (12/142) of the patients.
A history of gastritis and/or gastroesophageal reﬂux
disorders (GERD) was reported in 13.38% (19/142) of the
patients (10 in the Troxipide group and 9 in the Ranitidine
group) while prolonged therapy with nonsteroidal anti-
inﬂammatory drugs (NSAIDs) was reported in one patient
randomized to the Troxipide group. A total of 9.86%
(14/142) of the patients used concomitant medications like
domperidone, lactulose, and nystatin.
3.2. Gastroendoscopic Findings. As per the diagnosis by
endoscopy, the signs of gastritis were limited to the antrum
in 34.51% of the patients and limited to the corpus in 9.15%
of the patients while pangastritis was found in 54.93% of the
patients (Table 1). The endoscopic examination also revealed
that gastritis was either idiopathic (84.5%) or was associated
with the probable presence of H. pylori (7.75%), the usage
of drugs (4.23%), or other gastric irritants (3.52%). How-
ever, among the patients showing the probable endoscopic
presenceofH.pylori,onlytwopatients(bothfromTroxipide
group) had a corresponding positive serology.
3.3. Complete Resolution of Signs of Endoscopic Gastritis.
Among the 142 patients, a higher proportion of patients
receiving Troxipide showed complete endoscopic healing of
erosions (88.14% versus 56.36%), oozing (96.77% versus
78.95%), and edema (93.88% versus 46.51%) as compared
to Ranitidine (P<. 05).
Completeendoscopichealingwasalsofoundtobehigher
with Troxipide than Ranitidine among the patients showing
moderate to severe signs of endoscopic gastritis—85.71%
versus 41.66% for erosion, 71.43% versus 34.29% for redness
and 92% versus 41.18% for edema (P<. 01).
Twenty-seven of the patients receiving Troxipide and
seventeen of those receiving Ranitidine showed the presence
of all four endoscopic signs at baseline. Of these patients,
complete endoscopic healing was seen in 77.77% of the
patients (21/27) receiving Troxipide and 29.41% (5/17) of
those receiving Ranitidine (P<. 01; 95% CI: 16.8–79.9).
3.4. Improvement in Signs of Endoscopic Gastritis. The reduc-
tion in the mean severity scores of the various endoscopic
ﬁndings from baseline and week 4 were greater with
Troxipide than Ranitidine as seen in Table 2.
An improvement in the endoscopic gastritis was also
foundinagreaterproportion ofpatientsreceivingTroxipide:
gastric mucosal erosion (98.31% versus 78.18%), oozing
(97.77% versus 78.95%), redness (91.04% versus 71.43%),
and edema (97.96% versus 69.77%) as compared to Rani-
tidine at the end of therapy (P<. 05).
3.5. Clinical Symptom Relief. At the end of therapy duration,
a higher proportion of patients reported symptom relief
(reduction of at least 50 points on the VAS score from
baseline to follow up) with Troxipide: abdominal pain
(70.42% versus 19.72%), bloating (44.78% versus 18.46%),
belching (43.18% versus 20.51%), and heartburn (56.90%
versus 16.33%) as compared to Ranitidine (P<. 05). It was
also found that all these patients had moderate to severe
endoscopic gastritis at baseline.
3.6. Complete Symptom Resolution. Complete resolution of
the subjective symptoms reported at baseline was reported
in a statistically greater proportion of patients receiving
Troxipide as compared to Ranitidine (P<. 01) at the end
of week 4 as seen in Figure 1.4 Gastroenterology Research and Practice
Table 2: Mean four-point scale (FPS) scores for signs of endoscopic
Gastritis in patients at baseline and week 4.
Troxipide
mean VAS score
(±SD)
Ranitidine
mean VAS
score (±SD)
P values for
diﬀerence
between
treatments
Gastric Mucosal
Erosion
Baseline 2.58 ±0.95 2.17 ±0.84
Week 4 1.08 ±0.33
∗ 1.39 ±0.57
∗ <.01
Gastric mucosal
Oozing
Baseline 1.55 ±0.71 1.31 ±0.55
Week 4 1.01 ±0.21
∗ 1.06 ±0.23
∗ <.05
Gastric mucosal
Redness
Baseline 2.73 ±0.72 2.45 ±0.79
Week 4 1.28 ±0.48
∗ 1.65 ±0.63
∗ <.05
Gastric mucosal
Edema
Baseline 2.10 ± 0.91 1.87 ±0.84
Week 4 1.04 ±0.26
∗ 1.32 ±0.53
∗ <0.05
∗P Value less than .05 versus baseline, within the group.
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Figure 1: Complete symptom resolution in endoscopic gastritis
with Troxipide and Ranitidine. Percentage of patients at the end of
therapy (week 4) reporting complete symptom resolution (a VAS
score of 0 at week 4) with Troxipide and Ranitidine at the end of
treatment (∗P<. 01).
3.7. Improvement in Clinical Symptoms. Some positive
change in the severity of the subjective symptom was seen
in all the 142 patients participating in the study. However,
the reduction in the mean VAS score, at the end of week
2 and week 4, were found to be superior with Troxipide as
compared to Ranitidine (Table 3), especially for abdominal
pain,bloating,andheartburn(P<. 01).Symptomsimprove-
ment (a reduction in the VAS score of at least 20 points from
baseline to followup) was seen in a higher proportion of
Table 3: Mean Visual Analog Scale (VAS) scores for Gastritis
symptoms in patients at baseline, week 2 and week 4.
Troxipide
Mean VAS Score
(±SD)
Ranitidine
Mean VAS
Score (±SD)
P-values for
diﬀerence
between
treatments
Abdominal Pain
Baseline 61.55 ±11.66 56.47 ± 10.97
Week 2 34.78 ±10.67
∗ 37.04±10.87
∗ <.01
Week 4 10.98 ±9.43
∗ 22.67 ±9.70
∗ <.01
Bloating
Baseline 52.98 ±16.61 48.15 ± 18.94
Week 2 27.01 ±13.93
∗ 31.38±15.49
∗ <.01
Week 4 7.76 ± 10.56
∗ 16.92±14.78
∗ <.01
Belching
Baseline 43.41 ±20.11 42.58 ± 17.83
Week 2 20.23 ±16.21
∗ 23.84±14.43
∗ N.S
Week 4 2.04 ±6.32
∗ 10.51±13.16
∗ <.05
Nausea
Baseline 32.74 ±18.01 32.42 ± 15.82
Week 2 9.61 ± 11.48
∗ 14.6 ±13.58
∗ N.S
Week 4 0.19 ±1.40
∗ 3.4 ±8.72
∗ N.S
Vomiting
Baseline 17.85 ±14.23 20.0 ±11.54
Week 2 5.0 ± 11.6
∗ 3.84 ±5.06
∗ N.S
Week 4 0.0
∗ 0.76 ±2.77
∗ N.S
Loss of Appetite
Baseline 32.75 ±19.25 30.91 ± 19.97
Week 2 10.34 ±10.85
∗ 13.63±10.02
∗ N.S
Week 4 0.34 ±1.85
∗ 0.91 ±2.94
∗ N.S
Heartburn
Baseline 49.31 ±15.32 42.85 ± 16.58
Week 2 21.37 ±11.15
∗ 26.73±12.81
∗ <.01
Week 4 2.75 ±6.15
∗ 11.63 ±9.5
∗ <.01
∗P Value less than .01 versus baseline, within the group.
NS: not signiﬁcant (P>. 05).
patients with Troxipide as compared to Ranitidine in case of
abdominal pain, bloating, and heartburn (Figure 2).
3.8. Overall Safety and Tolerability Proﬁle. Mild to moderate
cases of constipation and headache were reported among
fourteen patients (four receiving Troxipide and ten receiving
Ranitidine). However, these adverse eﬀects did not warrant
discontinuation of the treatment and the overall tolerability
proﬁle of the study medications was not aﬀected.
The investigators and the patients also found Troxipide
to be a better tolerated drug than Ranitidine. A higher mean
proportion of patients and investigators rated its tolerability
asverygood(77.46%versus21.13%)orgood(21.84%versus
31.69%).Gastroenterology Research and Practice 5
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Figure 2: Clinical symptom improvement in endoscopic gastritis with Troxipide and Ranitidine. Percentage of patients at each followup
period(week 2and4)reportingclinicalsymptomimprovement(areductionintheVASscoreofatleast20pointsfrombaselinetofollowup)
for abdominal pain, bloating, and heartburn with Troxipide and Ranitidine (∗P<. 05 and ∗∗P<. 01).
4. Discussion
Gastrointestinal diseases such as gastritis have a signiﬁcant
impact on healthcare. As a result, healthcare providers must
devise ways to limit the expenditure while providing high-
qualitypatient care. In caseof gastritis treatment, the eﬃcacy
of the medication to be used should be considered, because
recurrence and complications resulting from ineﬀective
therapies can negatively aﬀect the patient’s quality of life
and increase the overall cost of healthcare [25]. Studies
have shown that patients receiving at least one prescription
of acid-suppressive agents had a substantial increase in
the risk of developing pancreatitis [26]. It has therefore
been suggested that cytoprotective drugs, which ultimately
balancetheaggressiveanddefensivefactors,maybethemore
appropriate means of controlling the disease [5, 7].
The present study, comparing Troxipide (100mg thrice a
day) with Ranitidine (150mg twice a day), has demonstrated
the role of Troxipide as an eﬀective prophylactic in patients
withendoscopicgastritis.Troxipidewasfoundtobringabout
an improvement in the severity of the signs of endoscopic
gastritis and various subjective clinical symptoms in nearly
96.27% and 81.23% of the patients, respectively. The VAS
scale used in this study is a validated outcome measure and
has been used successfully in many earlier studies [23, 24,
27]. In the validation of the VAS scale, a 20-point change
has been recommended as the benchmark of a clinically
signiﬁcant response [28, 29].
In patients with moderate to severe endoscopic gas-
tritis, Troxipide was more eﬀective than ranitidine in
bringing about complete endoscopic healing and clinical
symptom relief. The overall tolerability proﬁle as assessed
by the patients and investigators was also higher with
Troxipide.
One of the cardinal signs of GERD [30, 31], heartburn,
was considered as one of the important subjective symptoms
reported by patients. It is interesting to note that Troxipide
not only provides a higher proportion of patients with an
improvement in heartburn, but also provides it in a shorter
duration as compared to Ranitidine. This was evident from
the fact that by the second week, the patients receiving
Troxipide reported statistically comparable results to those
produced by Ranitidine after four weeks of therapy. It can
be concluded, therefore, that Troxipide may prove to be an
eﬃcient agent in the treatment of GERD.
The other major ﬁnding in this study is that the rate
of prevalence of H. pylori infection in this series was
exceptionally low, considering the study sample consisted
of a series of patients referred for endoscopy. It is also
striking that while the presence of H. pylori in the Indian
population is substantial [32, 33], only 3.5% (5/142) of the
study sample showed positive serology for H. pylori. The
literature search for a few Indian studies also revealed very
low incidence of 5.8%–17.7% of H. pylori infection among
the patients showing the endoscopic presence of gastritis
[34, 35]. In the earlier studies, the presence of H. pylori
in the study population has generally been conﬁrmed by
subjecting the biopsy sample to the rapid urease test, in
addition to either serology or the urease breath test [36, 37].
Additionally, the use of diﬀerent cutoﬀ points for the test
positivity in diﬀerent studies may lead to various sensitivities
and speciﬁcities. Thus, the incidence of H. pylori infection
can vary considerably among studies because of the selection
of the diagnostic test as well as the cutoﬀ points for test
positivity [38].
It is also known that additional investigations and inva-
sive procedures are required in patients only if the presence
of H. pylori has been identiﬁed along with the presence
of gastritis or dyspepsia related symptoms [39]. In the
presentstudy,however,thehistologicalaspectsofendoscopic
gastritis were not considered as part of the protocol. The
inclusion of a provision to extract biopsy samples for the
rapid urease test could probably have revealed the presence
of H. pylori in more patients.6 Gastroenterology Research and Practice
Current therapy focuses on eradication of H. pylori
in addition to the healing of gastritis. The Maastricht III
Consensus Report [40] also recommends a treatment for
weeks with triple eradication therapy, irrespective of the geo-
graphical region, which would ultimately results in the com-
plete resolution of gastritis. However, studies in the Indian
population have found that rate of eradication of H. pylori
using this triple therapy for one week has been lower than
those reported in the West [35, 41]. Troxipide may aid in the
improvement of this eradication rate, either as a monother-
apy or in combination with other currently used agents.
Although not signiﬁcant, a small subgroup of the current
study sample has shown complete eradication of H. pylori
and subsequent healing of endoscopic gastritis after four
weeksoftherapywithTroxipide.Thisisfurthersupportedby
earlier preclinical studies where Troxipide has been shown to
inhibit H. pylori derived urease, fMLP-like substances, and
myeloperoxidase activity as well as interleukin-8-induced
chemotaxis [11].Thereisaneed,however,forfurtherstudies
to evaluate the eﬀectiveness of Troxipide in patients with H.
pylori infection.
Studies evaluating the eﬃcacies of cytoprotective agents
in the treatment of nonulcer dyspepsia and nonerosive gas-
tritis have generally found them to be equally or marginally
more eﬃcacious than placebo [42, 43]. Interestingly, ran-
domized clinical trials comparing cytoprotective agents
with the acid-suppressive agent, Ranitidine, have observed
superior eﬃcacy with the former [44, 45]. These studies
have found that the global relief in symptoms is signiﬁcantly
more frequent with the cytoprotective agent than Ranitidine
[44]. Further, the cytoprotective agent was more eﬀective
than ranitidine in inducing healing or improvement of the
endoscopic and histological features of the disease [45].
The present study has also reported, in accordance to these
earlier studies, a better therapy outcome with Troxipide as
compared to Ranitidine.
Troxipide, in particular, has been extensively studied in
patients with gastritis and gastric ulcer [8–10]. Pooled data
from studies evaluating the eﬃcacy of Troxipide in over 300
patients with gastritis or acute gastric mucosal lesions of
chronic gastritis have demonstrated an overall amelioration
rate of 82.9% [9]. Similarly, an amelioration rate of 79.4%
has been reported among 514 patients with gastric ulcer
[9]. The ﬁndings of the current study, using an indigenously
prepared Troxipide sample [46], are in accordance with these
earlier studies.
In addition to superior eﬃcacy, the tolerability of the
medication will have an impact on its compliance among
the patient population. In the present study, patients found
Troxipide to be better tolerable than Ranitidine, which
in addition to its good eﬃcacy proﬁle makes Troxipide a
suitable prophylactic agent.
This study demonstrates that Troxipide (300mg) is
more eﬀective than Ranitidine (300mg) in controlling the
subjective symptoms and endoscopic ﬁndings in patients
with moderate to severe gastritis in the primary care setting.
Thus, it establishes the appropriateness of a Troxipide-based
treatment strategy for primary care practice patients.
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